Koers Kane Biotech Inc Toronto S.E.
Aandelen
KNE
CA4838092084
Biotechnologie & Medisch Onderzoek
Omzet 2022 | 2,67 mln. 1,95 mln. 1,79 mln. | Omzet 2023 | 149K 109K 99,96K | Marktkapitalisatie | 10,55 mln. 7,7 mln. 7,08 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -3 mln. -2,19 mln. -2,01 mln. | Nettowinst (verlies) 2023 | -5 mln. -3,65 mln. -3,35 mln. | EV/omzet 2022 | 6,37 x |
Nettoschuld 2022 | 5,76 mln. 4,21 mln. 3,86 mln. | Nettoschuld 2023 | 8,51 mln. 6,22 mln. 5,71 mln. | EV/omzet 2023 | 128 x |
K/w-verhouding 2022 |
-2,79
x | K/w-verhouding 2023 |
-2,02
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 65,07% |
Recentste transcriptie over Kane Biotech Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Marc Edwards
CEO | Chief Executive Officer | - | 02-06-16 |
Ray Dupuis
DFI | Director of Finance/CFO | - | 05-09-17 |
Gregory Schultz
CTO | Chief Tech/Sci/R&D Officer | 73 | 05-04-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
R. Renaud
BRD | Director/Board Member | - | 15-09-10 |
Chairman | 59 | 20/02 | |
Georges Morin
BRD | Director/Board Member | - | 20-05-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+55,55% | 59,28 mld. | |
+43,45% | 40,94 mld. | |
-4,71% | 40,17 mld. | |
-5,56% | 28,69 mld. | |
+13,76% | 26,63 mld. | |
-22,00% | 18,89 mld. | |
+31,50% | 12,46 mld. | |
+2,16% | 12,42 mld. | |
+25,70% | 12,26 mld. |